MorphoSys AG (MOR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

MorphoSys AG (MOR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH81760D
  • |
  • Pages: 60
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

MorphoSys AG (Morphosys) is a pharmaceutical company that develops monoclonal antibodies for therapeutic, diagnostic and research applications. The company offers therapeutic drugs for various diseases including cancer, rheumatoid arthritis and Alzheimer's diseases. It patented antibody library technologies including HuCAL are used in research and diagnostics applications. Morphosys product pipeline includes drugs for the treatment of different types of cancer, psoriasis, rheumatoid arthritis, COPD, asthma and other inflammatory diseases. The company has its pipelines in the biopharmaceutical industry. It has its research and development activities with pharmaceutical and biotechnology companies. Morphosys is headquartered in Martinsried, Germany.

MorphoSys AG (MOR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

MorphoSys AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

MorphoSys AG, Medical Devices Deals, 2011 to YTD 2017 10

MorphoSys AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

MorphoSys AG, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Lanthio Pharma Raises US$6 Million In Series A Financing 13

Partnerships 14

MorphoSys Enters into Agreement with LEO Pharma 14

MorphoSys Partners with University of Texas MD Anderson Cancer Center 14

MorphoSys Enters into Agreement with Immatics Biotech 15

MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 16

MorphoSys And Temple University Enter Into Agreement To Discover Therapeutic Antibody 17

MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 18

MorphoSys Enters Into Co-Development Agreement With Lanthio Pharma 19

MorphoSys Expands Co-Development Agreement With Novartis For Therapeutic Antibodies 20

Licensing Agreements 21

Emergent BioSolutions Enters into Amended Licensing Agreement with MorphoSys for ES-414 21

MorphoSys Exercises Option to License Lanthipeptide Technology from Lanthio Pharma 22

MorphoSys Enters into Licensing Agreement with Merck Serono 23

MorphoSys Enters Into Licensing Agreement With GSK For MOR103 24

MorphoSys Enters Into Licensing Agreement With BioPharma Company For Slonomics Technology 25

Lanthio Pharma Enters Into Licensing Agreement With Tarix Pharma For Lanthionine Angiotensin-(1-7) Agonistic Peptide 26

MorphoSys Enters Into Licensing Agreement With Novozymes 27

MorphoSys Expands Licensing Agreement With Shionogi 28

Genedata Expands Licensing Agreement with MorphoSys 29

Equity Offering 30

MorphoSys Raises USD124.3 Million in Private Placement of Shares 30

MorphoSys Completes Private Placement Of Shares For US$112.7 Million 31

Acquisition 32

MorphoSys Acquires Lanthio Pharma for USD22.5 Million 32

Bio-Rad Labs Completes Acquisition Of AbD Serotec From MorphoSys For US$70 Million 33

MorphoSys AG-Key Competitors 36

Key Employees 37

Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 39

Financial Announcements 39

Nov 07, 2016: MorphoSys Reports Results for the First Nine Months of 2016 39

Aug 01, 2016: MorphoSys Reports Results for the First Six Months of 2016 41

May 03, 2016: MorphoSys Reports Results for the First Three Months of 2016 43

Mar 02, 2016: MorphoSys Reports Results for Fiscal Year 2015 45

Mar 02, 2016: MorphoSys is in a strong financial position and focuses on own pipeline 48

Corporate Communications 49

Sep 19, 2016: Lanthio Pharma Expands Management Team: Axel Mescheder M.D. Appointed Chief Medical Officer (CMO) of MorphoSyss Dutch Lanthipeptide Subsidiary 49

Product News 50

09/19/2016: Lanthio Pharma Expands Management Team: Axel Mescheder M.D. Appointed Chief Medical Officer (CMO) of MorphoSys's Dutch Lanthipeptide Subsidiary 50

09/06/2016: MorphoSys Initiates Phase 2/3 Trial of CD19 Antibody MOR208 plus Bendamustine in Patients with Relapsed or Refractory DLBCL 51

Clinical Trials 53

Feb 21, 2017: MorphoSys's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107 53

Aug 03, 2016: MorphoSys Successfully Completes Safety Run-in of MOR208 in L-MIND Combination Study in Patients with DLBCL 54

Jun 17, 2016: MorphoSys Reports Publication of Clinical Case Report of a Blood Cancer (DLBCL) Patient Showing Long-Lasting Complete Remission of Currently 26 Months under MOR208 Treatment 55

Jun 06, 2016: MorphoSys Presents Updated Clinical Data for MOR208 in Non-Hodgkins Lymphoma at ASCO 2016 57

Apr 06, 2016: MorphoSys Initiates Phase 2 Combination Trial of MOR208 and Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma 58

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59

List of Figures

MorphoSys AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

MorphoSys AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

MorphoSys AG, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

MorphoSys AG, Pharmaceuticals & Healthcare, Key Facts, 2015 1

MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

MorphoSys AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

MorphoSys AG, Deals By Therapy Area, 2011 to YTD 2017 9

MorphoSys AG, Medical Devices Deals, 2011 to YTD 2017 10

MorphoSys AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Lanthio Pharma Raises US$6 Million In Series A Financing 13

MorphoSys Enters into Agreement with LEO Pharma 14

MorphoSys Partners with University of Texas MD Anderson Cancer Center 14

MorphoSys Enters into Agreement with Immatics Biotech 15

MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 16

MorphoSys And Temple University Enter Into Agreement To Discover Therapeutic Antibody 17

MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 18

MorphoSys Enters Into Co-Development Agreement With Lanthio Pharma 19

MorphoSys Expands Co-Development Agreement With Novartis For Therapeutic Antibodies 20

Emergent BioSolutions Enters into Amended Licensing Agreement with MorphoSys for ES-414 21

MorphoSys Exercises Option to License Lanthipeptide Technology from Lanthio Pharma 22

MorphoSys Enters into Licensing Agreement with Merck Serono 23

MorphoSys Enters Into Licensing Agreement With GSK For MOR103 24

MorphoSys Enters Into Licensing Agreement With BioPharma Company For Slonomics Technology 25

Lanthio Pharma Enters Into Licensing Agreement With Tarix Pharma For Lanthionine Angiotensin-(1-7) Agonistic Peptide 26

MorphoSys Enters Into Licensing Agreement With Novozymes 27

MorphoSys Expands Licensing Agreement With Shionogi 28

Genedata Expands Licensing Agreement with MorphoSys 29

MorphoSys Raises USD124.3 Million in Private Placement of Shares 30

MorphoSys Completes Private Placement Of Shares For US$112.7 Million 31

MorphoSys Acquires Lanthio Pharma for USD22.5 Million 32

Bio-Rad Labs Completes Acquisition Of AbD Serotec From MorphoSys For US$70 Million 33

MorphoSys AG, Key Competitors 36

MorphoSys AG, Key Employees 37

MorphoSys AG, Subsidiaries 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

MorphoSys AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16020
Site License
USD 500 INR 32040
Corporate User License
USD 750 INR 48060

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com